Clearside Biomedical Inc (CLSD)
1.035
+0.02
(+2.48%)
USD |
NASDAQ |
Nov 04, 16:00
1.06
+0.02
(+2.42%)
After-Hours: 20:00
Clearside Biomedical Net Income (Quarterly): -7.594M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -7.594M |
| March 31, 2024 | -11.76M |
| December 31, 2023 | -4.832M |
| September 30, 2023 | -9.267M |
| June 30, 2023 | -9.106M |
| March 31, 2023 | -9.28M |
| December 31, 2022 | -9.663M |
| September 30, 2022 | -7.827M |
| June 30, 2022 | -7.813M |
| March 31, 2022 | -7.644M |
| December 31, 2021 | 18.71M |
| September 30, 2021 | -4.887M |
| June 30, 2021 | -6.095M |
| March 31, 2021 | -7.351M |
| December 31, 2020 | -7.112M |
| September 30, 2020 | -2.433M |
| June 30, 2020 | -5.754M |
| March 31, 2020 | -2.911M |
| December 31, 2019 | -3.096M |
| September 30, 2019 | -6.536M |
| Date | Value |
|---|---|
| June 30, 2019 | -5.734M |
| March 31, 2019 | -15.40M |
| December 31, 2018 | -21.64M |
| September 30, 2018 | -23.87M |
| June 30, 2018 | -20.70M |
| March 31, 2018 | -16.61M |
| December 31, 2017 | -16.49M |
| September 30, 2017 | -18.34M |
| June 30, 2017 | -13.77M |
| March 31, 2017 | -10.37M |
| December 31, 2016 | -9.686M |
| September 30, 2016 | -5.645M |
| June 30, 2016 | -5.102M |
| March 31, 2016 | -5.449M |
| December 31, 2015 | -5.17M |
| September 30, 2015 | -3.475M |
| June 30, 2015 | -5.237M |
| March 31, 2015 | -3.757M |
| December 31, 2014 | -2.663M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-11.76M
Minimum
Mar 2024
18.71M
Maximum
Dec 2021
-5.564M
Average
-7.351M
Median
Mar 2021
Net Income (Quarterly) Benchmarks
| Viking Therapeutics Inc | -24.94M |
| Arcus Biosciences Inc | -93.00M |
| Crinetics Pharmaceuticals Inc | -74.06M |
| Biomea Fusion Inc | -32.79M |
| NovaBay Pharmaceuticals Inc | -1.585M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.09M |
| Total Expenses (Quarterly) | 7.68M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 48.00M |
| Profit Margin (Quarterly) | -8.44K% |
| Earnings Yield | -48.31% |
| Normalized Earnings Yield | -48.31 |